 Our group has noted that we are seeing an increase in the number of consultations for women treated with psychostimulants in combination with an antidepressant.  The reasons vary.  Some women have depression and comorbid [...]
An updated version of this post can be found HERE. Two thirds of all breast cancer tumors are known to have receptors that respond to hormones; that is they can grow in response to estrogen. [...]
 Multiple studies have demonstrated the effectiveness of antidepressant medications for the treatment of postpartum depression (PPD).  Most of the these studies focused on the impact of these medications on depressive symptoms; however, it is [...]
Women face difficult choices when deciding whether or not to continue psychiatric medications during pregnancy. Â This choice can be especially difficult for women taking newer medications which lack adequate reproductive safety data. Â While we have [...]
Which treatment is best for managing menopausal sleep problems? We tend to think of estrogen replacement therapy as being the best option for all menopausal symptoms; however, there are other options for managing menopausal symptoms, [...]
In healthy perimenopausal women with hot flashes, treatment with both estradiol and venlafaxine resulted in significantly greater improvement in quality of life, as compared to placebo. Estradiol had beneficial treatment effects on all domains of the [...]
Over the last few years, we have reported on several studies which have suggested an increased risk of certain types of cardiovascular malformations among children exposed to selective serotonin reuptake inhibitors (SSRIs) during pregnancy. The first reports [...]
While many midlife women are interested in pursuing non-hormonal options for the treatment of menopausal symptoms, they are understandably concerned about taking antidepressant medications, such as SSRIs and SNRIs, that, while effective for treating hot [...]
Various selective serotonin reuptake inhibitors (SSRIs), including citalopram (Celexa), escitalopram (Lexapro) and paroxetine (Paxil), have been shown to be effective for the treatment of menopausal vasomotor symptoms (VMS). Other studies have supported the efficacy of the serotonin–norepinephrine reuptake inhibitors (SNRIs) duloxetine (Cymbalta) and venlafaxine (Effexor). The FDA recently approved a 7.5-mg formulation of paroxetine (marketed as Brisdelle) as the first non-hormonal treatment of hot flashes.
While data accumulated over the last 30 years suggest that certain antidepressants may be used with relative safety during pregnancy, our knowledge regarding the risks of prenatal exposure to psychotropic medications is incomplete. Because neuronal migration and differentiation occur throughout pregnancy and into the early years of life, development of the central nervous system (CNS) remains particularly vulnerable throughout pregnancy.
